A new frontier in targeted protein degradation
We are harnessing the natural machinery of the lysosome to selectively target and degrade extracellular pathogenic proteins
Led by a team of pharma and biotech industry veterans and backed by leading European life sciences investors, we are building a differentiated, oral small molecule extracellular protein degrader platform. Our platform has broad applicability across a broad range of diseases, that are difficult to target with existing modalities
